Date:		6/10/2022
Your Name:		Peter Kosa
Manuscript Title:		Enhancing clinical value of serum neurofilament light chain measurement
Mar	nuscript Number (if k	nown): _161415-INS-CMED-RV-2
In the interest of transparency, we content of your manuscript. "Rela affected by the content of the ma indicate a bias. If you are in doub?  The author's relationships/activitic epidemiology of hypertension, you that medication is not mentioned		all support for the work reported in this manuscript without time limit. For all other items, the time
		Name all entities with whom you have this relationship or indicate none (add rows as needed)  Specifications/Comments (e.g., if payments were made to you or to your institution)  Time frame: Since the initial planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health  Click the tab key to add additional rows.
		Time frame: past 36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	None None
3	Royalties or licenses	None None

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None None	
6	Payment for expert testimony	■ None	
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or pending	None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	■ None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options	[⊠] None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None	
13	Other financial or non-financial interests	None	
Plea [⊠]	-	t to the following statement to indicate your agreeme answered every question and have not altered the wo	

Date:		-	6/10/2022		
Your Name:		-	Ruturaj Masvekar		
Manuscript Title:		-	Enhancing clinical value of serum neurofilament light chain measurement		
Mar	nuscript Number (if k	(nown):	161415-INS-CMED-RV-2		
In the interest of transparency, we content of your manuscript. "Rela affected by the content of the maindicate a bias. If you are in doubt."  The author's relationships/activitic epidemiology of hypertension, you that medication is not mentioned.		ipt. "Rela of the mar e in doubt os/activitie nsion, you entioned i all suppor	ted" means any relation with for-profit or no nuscript. Disclosure represents a commitme about whether to list a relationship/activity es/interests should be defined broadly. For each should declare all relationships with manufain the manuscript.	/interest, it is preferable that you do so.	
			entities with whom you have this hip or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)	
			Time frame: Since the initial planning	of the work	
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	Division of Allers	one of Intramural Research, National Institute gy and Infectious Diseases, National es of Health	Click the tab key to add additional rows.	
1	present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for	Division of Allers	of Intramural Research, National Institute gy and Infectious Diseases, National		
2	present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for	Division of Allerg Institute	n of Intramural Research, National Institute gy and Infectious Diseases, National es of Health		

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None None	
6	Payment for expert testimony	■ None	
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or pending	None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	■ None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options	None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None	
13	Other financial or non-financial interests	None	
Plea 🖂	-	t to the following statement to indicate your agreeme answered every question and have not altered the wo	

Date:		-	6/10/2022		
Your Name:			Mika Komori		
Manuscript Title:		<u>-</u>	Enhancing clinical value of serum neurofilament	ight chain measurement	
Maı	nuscript Number (if k	known):	161415-INS-CMED-RV-2		
In the interest of transparency, we content of your manuscript. "Rela affected by the content of the mar indicate a bias. If you are in doubt The author's relationships/activitie epidemiology of hypertension, you that medication is not mentioned In item #1 below, report all support			ted" means any relation with for-profit or no nuscript. Disclosure represents a commitme about whether to list a relationship/activity es/interests should be defined broadly. For each of the u should declare all relationships with manufain the manuscript.	/interest, it is preferable that you do so.	
		.c past co			
			entities with whom you have this hip or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)	
			Time frame: Since the initial planning	of the work	
4					
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	Division of Aller	one of Intramural Research, National Institute gy and Infectious Diseases, National es of Health	Click the tab key to add additional rows.	
	present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for	Division of Aller	of Intramural Research, National Institute gy and Infectious Diseases, National		
2	present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for	Division of Aller Institute	n of Intramural Research, National Institute gy and Infectious Diseases, National es of Health		

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	□ None  Eli Lilly, Kobe, Japan	
6	Payment for expert testimony	[⊠]   None	
7	Support for attending meetings and/or travel	[⊠] None	
8	Patents planned, issued or pending	None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options	None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None	
13	Other financial or non-financial interests	None	
Plea [⊠]	-	t to the following statement to indicate your agreeme answered every question and have not altered the wo	

Date	e:		6/10/2022		
Your Name:			Jonathan Phillips		
Manuscript Title:			Enhancing clinical value of serum neurofilament light chain measurement		
Mar	nuscript Number (if k	nown):	161415-INS-CMED-RV-2		
In the interest of transparency, we content of your manuscript. "Rela affected by the content of the mar indicate a bias. If you are in doubt The author's relationships/activitie epidemiology of hypertension, you that medication is not mentioned in the content of the content			nted" means any relation with for-profit or no nuscript. Disclosure represents a commitmer t about whether to list a relationship/activity, es/interests should be defined broadly. For e u should declare all relationships with manufa in the manuscript.	/interest, it is preferable that you do so.	
			l entities with whom you have this ship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)	
			Time frame: Since the initial planning of	of the work	
	All support for the present manuscript (e.g., funding, provision of study materials,	Division	one n of Intramural Research, National Institute gy and Infectious Diseases, National		
	medical writing, article processing charges, etc.) No time limit for this item.		es of Health	Click the tab key to add additional rows.	
	article processing charges, etc.) No time limit for		Time frame: past 36 months		
2	article processing charges, etc.) No time limit for				

			ations/Comments (e.g., if payments were you or to your institution)
4	Consulting fees	None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None	
6	Payment for expert testimony	None	
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or pending	None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	■ None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	■ None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options	None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None	
13	Other financial or non-financial interests	None	
Plea [⊠]	-	t to the following statement to indicate your agreeme answered every question and have not altered the wo	

Date:		6/10/2022
Your Name:		Vighnesh Ramesh
Manuscript Title:		Enhancing clinical value of serum neurofilament light chain measurement
Mai	nuscript Number (if k	own): 161415-INS-CMED-RV-2
In the interest of transparency, we content of your manuscript. "Rela affected by the content of the maindicate a bias. If you are in doubt."  The author's relationships/activitic epidemiology of hypertension, you that medication is not mentioned.		ency, we ask you to disclose all relationships/activities/interests listed below that are related to the t. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be the manuscript. Disclosure represents a commitment to transparency and does not necessarily in doubt about whether to list a relationship/activity/interest, it is preferable that you do so. "Activities/interests should be defined broadly. For example, if your manuscript pertains to the sion, you should declare all relationships with manufacturers of antihypertensive medication, even if nationed in the manuscript.  I support for the work reported in this manuscript without time limit. For all other items, the time past 36 months.
II ai	ne for disclosure is the	past 50 months.
		Specifications/Comments (e.g., if payments were elationship or indicate none (add rows as needed)  Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for	Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health  Click the tab key to add additional rows.
	this item.	
		Time frame: past 36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	None
3	Royalties or licenses	None     Non

			ations/Comments (e.g., if payments were you or to your institution)
4	Consulting fees	None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None	
6	Payment for expert testimony	None	
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or pending	None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	■ None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	■ None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)	
11	Stock or stock options	None		
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None		
13	Other financial or non-financial interests	None		
Plea [⊠]	Please place an "X" next to the following statement to indicate your agreement:			

Dat	e:	_	6/10/2022		
Your Name:		_	Mihael Varosanec		
Manuscript Title:		_	Enhancing clinical value of serum neurofilament light chain measurement		
Ма	nuscript Number (if kr	nown):	161415-INS-CMED-RV-2		
In the interest of transparency, we content of your manuscript. "Rela affected by the content of the maindicate a bias. If you are in doubt."  The author's relationships/activitic epidemiology of hypertension, you that medication is not mentioned.			e ask you to disclose all relationships/activities/interests listed below that are related to the ited" means any relation with for-profit or not-for-profit third parties whose interests may be nuscript. Disclosure represents a commitment to transparency and does not necessarily about whether to list a relationship/activity/interest, it is preferable that you do so.  es/interests should be defined broadly. For example, if your manuscript pertains to the u should declare all relationships with manufacturers of antihypertensive medication, even if in the manuscript.		
frar	me for disclosure is the	e past 36 i	months.		
			entities with whom you have this hip or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)	
			Time frame: Since the initial planning	of the work	
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	of Allerg	of Intramural Research, National Institute gy and Infectious Diseases, National es of Health	Click the tab key to add additional rows.	
1	present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for	Division of Allerg	of Intramural Research, National Institute gy and Infectious Diseases, National		
2	present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for	Division of Allerg	of Intramural Research, National Institute gy and Infectious Diseases, National es of Health  Time frame: past 36 month		

			ations/Comments (e.g., if payments were you or to your institution)
4	Consulting fees	None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None	
6	Payment for expert testimony	None	
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or pending	None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	■ None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	■ None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)	
11	Stock or stock options	None		
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None		
13	Other financial or non-financial interests	None		
Plea [⊠]	Please place an "X" next to the following statement to indicate your agreement:			

Date	2:		6/10/2022		
Your Name:			Mary Sandford		
Manuscript Title:			Enhancing clinical value of serum neurofilament light chain measurement		
Man	uscript Number (if I	known):	161415-INS-CMED-RV-2		
In the interest of transparency, we content of your manuscript. "Rela affected by the content of the ma indicate a bias. If you are in doub?  The author's relationships/activitic epidemiology of hypertension, you that medication is not mentioned		ript. "Rela of the man e in double os/activition ension, you entioned	rt for the work reported in this manuscript without time limit. For all other items, the time		
			l entities with whom you have this ship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)	
			Time frame: Since the initial planning	of the work	
	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	Division of Aller	n of Intramural Research, National Institute rgy and Infectious Diseases, National res of Health	Click the tab key to add additional rows.	
2	Grants or contracts from any entity (if not indicated in item #1 above).	⊠ Ne	Time frame: past 36 month		
3	Royalties or licenses	⊠ No	one		

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	None None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None None	
6	Payment for expert testimony	■ None	
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or pending	None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	■ None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)	
11	Stock or stock options	None		
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None		
13	Other financial or non-financial interests	None		
Plea [🖂]	Please place an "X" next to the following statement to indicate your agreement:    I certify that I have answered every question and have not altered the wording of any of the questions on this form.			

Date:		6/10/2022				
Your Name:		Bibiana Bielekova	Bibiana Bielekova			
Manuscript Title:		Enhancing clinical value of serum neurofilame	Enhancing clinical value of serum neurofilament light chain measurement			
Ma	nuscript Number (if kr	own): 161415-INS-CMED-RV-2				
con affe	In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.					
The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.						
In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.						
		Name all entities with whom you have this relationship or indicate none (add rows as neede	Specifications/Comments (e.g., if payments were made to you or to your institution)			
		<del>-</del>	made to you or to your institution)			
1		elationship or indicate none (add rows as neede	made to you or to your institution)  ng of the work			
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for	Time frame: Since the initial plann  None  Division of Intramural Research, National Institut of Allergy and Infectious Diseases, National	made to you or to your institution)  ng of the work  Click the tab key to add additional rows.			

22 12/13/2021 ICMJE Disclosure Form

any entity (if not indicated in item #1 above).

Royalties or

licenses

**⊠** None

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	None None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None None	
6	Payment for expert testimony	■ None	
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or pending	None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	■ None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)	
11	Stock or stock options	None		
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None		
13	Other financial or non-financial interests	None		
Plea [🖂]	Please place an "X" next to the following statement to indicate your agreement:    I certify that I have answered every question and have not altered the wording of any of the questions on this form.			

# The Journal of Clinical Investigation

Click on boxes to check/uncheck items.

# Checklist for submitting a revised Clinical Medicine manuscript

In addition to addressing the items noted in the decision letter regarding your manuscript, ensure that your revised manuscript adheres to the guidelines below. For full submission details, visit the JCI website.

# Required files

# Manuscript

PDF of a clean version of the entire manuscript; include references, figures, figure legends, and tables. PDF of a marked-up version of the entire manuscript showing revisions and beginning with a point-by-point response to reviewer comments.

Word or RTF file of all manuscript text; include references, figure legends, tables, and table legends (<u>but not</u> figures, images, markup, or point-by-point responses).

Single PDF file of completed ICMIE uniform disclosure forms from all authors.

For clinical trials, a PDF of the appropriate reporting checklist (CONSORT, STROBE. etc.).

#### **Figures**

Publication-quality figures in TIFF format. See detailed instructions for figure preparation. Recommended: Graphical abstract (details available here).

# **Supplemental material**

Supplemental information, figures, and modest-sized tables, as:

- (a) (if applicable) a PDF in which reviewer-requested changes are highlighted
- (b) a clean, publication-quality PDF

Upload any supplemental videos and/or large spreadsheets separately.

Before submission, carefully review all supplemental files; they will not be checked by a copy editor. The Journal is not responsible for any errors contained in supplemental material.

# **Gels and blots**

For any figure showing a cropped blot or gel: a PDF, PPT, or PPTX file (distinct from any other supplemental material) that shows the entire unedited image.

Annotate each image as, e.g., "Full unedited gel for Figure 2B."

Clearly indicate which bands were used for the figures.

# Formatting and style

Recommended 9,000/maximum 12,000 words (including title page, full text, references, figure legends,

Double-spaced throughout, including references and tables; figure legends may be single spaced if necessary to keep a figure and its legend on the same page.

All pages are numbered.

Each section begins on a new page.

# **Abbreviations and acronyms**

Standard JCI abbreviations and acronyms are used without definition.

All other abbreviations and acronyms are spelled out at first use in the Abstract and again at first use in the main text (with the abbreviated form appearing in parentheses) and used without definition thereafter.

# **Gene names and symbols**

Gene names and symbols conform to official NCBI Gene Nomenclature.

Presented according to JCI Gene nomenclature and style.

# Italicization

Generally reserved for gene symbols, genotypes, and species names.

Terms such as in vivo, in vitro, etc., are not italicized.

# Unpublished data, manuscripts in preparation or under review, and personal communications

Cited parenthetically in the text, not as numbered references; e.g., "(Jane L. Doe, UCLA, Los Angeles, California, USA, unpublished observations)."

Written permission to cite unpublished observations by individuals external to the author's research team (email is sufficient) is submitted.

#### **Reference citations**

Appear in parentheses preceded by a space, e.g., "as described previously (1, 2)"; "several research groups (4–10) have found."

No superscript, boldface, italics, etc.

# Figure and table callouts

Figures and tables are called out in numerical order.

"Figure," "Table," "Supplemental Figure," "Supplemental Table," etc., are spelled out.
Callouts appear in parentheses (no boldface or italics) preceded by a space, unless grammatically part of the sentence: "the levels increased (Figure 5A)"; "data shown in Table 2."
Parts are called out as, e.g., "Figure 1A," "Figure 2, A and B," "Figure 3, B–D."

# Manuscript preparation and required reporting

# Title page

# Manuscript title

Clear, concise, and limited to 15 words, including conjunctions.

Refers to the relevant disease or disease model studied.

No subtitles, colons, periods, or nonstandard abbreviations.

# **Authors and affiliations**

Author names are provided in full (for example, "Benita J. Sjögren") and in the appropriate order. No titles, honorifics, degrees, or certifications.

Affiliations correspond to the period when the work was performed.

For authors whose affiliation has changed since completion of the work, specify the present affiliation and location below the numbered list.

Affiliation footnotes are assigned consecutively using superscripted numbers (1, 2, 3, etc.).

Affiliations include departments, institutions, city, state (if applicable), and country (but not mailing addresses or zip/regional codes).

Corresponding author's complete name, address, telephone number (including country code if applicable), and email address.

Consortium/study groups shown as authors (e.g., CARDIoGRAM Consortium)

Unless the members of the group appear as authors, each individual member and their affiliation are listed in the supplemental material, under the heading Supplemental Acknowledgments.

The following sentence appears in Acknowledgments: "See Supplemental Acknowledgments for details on {name of consortium}."

# **Conflict-of-interest statement**

A statement consistent with the Journal's conflict-of-interest policy is included; if no author has a conflict, state the following: "The authors have declared that no conflict of interest exists."

If patents are involved, the patent or patent application number(s) are provided and the names of the associated authors specified.

#### Abstract

<u>Structured format</u> with the sections Background, Methods, Results, Conclusion, Trial registration, Funding.

Maximum 250 words.

No references.

All nonstandard abbreviations are defined at first use.

# Main text (presented in the following order)

# Introduction

# Results

# Discussion

#### Methods

Demographic reporting (see details here)

incomplete, an explanation is provided.

Reporting on race and ethnicity adheres to NIH guidelines or other applicable authoritative standards.

Descriptors for any demographic identities are clear, unbiased, and up-to-date.

Data for any demographic variable are inclusive; if any information is unavailable or

Specify whether the participants or investigators made the classifications; and whether the options were defined by the investigators or participants.

Complete manufacturer name (omit location) is provided for each proprietary item used. For animal models, precise genotype, strain, number of backcrosses, sex, age, and source are specified.

Antibodies: Commercial — source and catalog/clone number are specified for each; custom — generation of antibodies is described (or an appropriate reference is cited).

Source of all cell lines used is indicated.

Data sets for gene expression microarrays, SNP arrays, and high-throughput sequencing studies are deposited in a public repository, and accession number(s) provided in Methods in the main text (for publication, data must be publicly available).

#### Statistics

Section appears near the end of Methods (before "Study approval").

The *P* value used to determine significance of differences is specified; e.g., "A *P* value less than 0.05 was considered significant."

Analysis appropriately corrects for multiple comparisons (more than 2 groups) and for repeated measures (multiple measurements within subjects).

If samples were excluded, a statement describes inclusion/exclusion criteria.

# Study approval

Stand-alone paragraph at the end of Methods.

Declaration of approval of human and/or animal studies, specifying the official name and location of the applicable institutional review board(s).

For human studies, a statement indicates receipt of written informed consent from participants and/or their parents/guardians.

For use of photographs of participants, a separate statement of written informed consent is included.

#### **Author contributions**

Contribution of each author (identified by initials) is specified; e.g., designing research studies, conducting experiments, acquiring data, analyzing data, providing reagents, writing the manuscript. Multiple contributions may be listed for a single individual, and more than one individual may be associated with a single contribution.

Grammatically complete sentences are used.

For manuscripts with 2 or more co-first authors, the method used to assign authorship order among these authors is stated.

#### Acknowledgments

States sources of support in the form of grants, equipment, or drugs.

Grant numbers are provided as applicable.

Other acknowledgments, such as of colleagues for advice, are included as appropriate.

# References

Prepared according to How to prepare references for submission.

# Figure legends

Maximum 300 words.

Each begins with a stand-alone title, irrespective of the individual parts.

Figure parts are called out in boldface: (A), (B-D), (C and E).

Symbols and abbreviations introduced in figures are defined and used consistently throughout. Use of terms within the legends is consistent with that in the figures themselves.

In each figure legend where appropriate, the statistical test(s) used are described.

For each panel representing multiple experiments, the exact number of samples (n) is reported. For representative experiments, the number of times the experiment was conducted is reported.

Error bars are defined either in Statistics or in the individual legends; e.g., "Data represent mean ± SEM."

Variance around the mean and statistical analysis are not provided for figures representing fewer than 3 independent samples.

For histological panels and insets, scale bars are defined or total original magnification is specified in the legends.

# **Figures**

Prepared according to How to prepare figures for submission.

For clinical trials, the appropriate flow diagram appears as a figure.

Parts are labeled with capital letters: A, B, C, etc., with no designated subparts.

Graphs of quantitative data are presented as either dot plots, with average and appropriate error bars indicated; or box-and-whisker plots, with values defined in the legend (bounds of the boxes, lines within the boxes, whiskers, and any outlying values). Dynamite plunger plots are not permitted.

If lanes in a gel or blot image are spliced together into a composite image, the lanes are distinguished with a thin vertical dividing line (black on a gray background; or white on a black background). State in the legend that the lanes were run on the same gel but were noncontiguous.

# **Tables**

Prepared in Word table format (not pasted in from another application).

 ${\bf Self\text{-}contained\ and\ self\text{-}explanatory}.$ 

Preceded by brief titles.

Each table fits on a single page and is presented on its own page.

Callouts to footnotes (designated with superscript capital letters) are assigned alphabetically row by row.

No subparts or subsections (for example, Table 1A and Table 1B).

Column headings in tables apply to all values throughout the column; a new row of column headings may not be introduced within a table.

See "Methods" above for reporting on demographics.